Perioperative immunotherapy for resectable hepatocellular carcinoma.
APA
Jin W, Xue M, Luo S (2026). Perioperative immunotherapy for resectable hepatocellular carcinoma.. Lancet (London, England), 407(10536), 1332-1334. https://doi.org/10.1016/S0140-6736(26)00142-X
MLA
Jin W, et al.. "Perioperative immunotherapy for resectable hepatocellular carcinoma.." Lancet (London, England), vol. 407, no. 10536, 2026, pp. 1332-1334.
PMID
41936364
같은 제1저자의 인용 많은 논문 (5)
- Transmembrane Protein TMEM59L Modulates 5-FU Resistance via PTPRN-Mediated DNA Damage Repair in Colorectal Cancer.
- Structure-based discovery of a novel allosteric activator of ATG4B for the treatment of triple-negative breast cancer.
- A Novel MICB-Targeting CAR-NK Cells for the Treatment of Pancreatic Cancer.
- A CD36-Targeting Thermosensitive Berberine Nanogel Blocks Tumor Lipid Hijacking and Potentiates Anti-PD-L1 Immunotherapy in Triple-Negative Breast Cancer.
- Transcriptome Analyses Reveal the Important miRNAs Involved in Immune Response of Gastric Cancer.